Studies on the measurement of patient experience of trial participation is scarce. Notwithstanding that this type of measurement could improve trial design and delivery, recruitment, retention, long-term patient engagement with trials and overall enhance the patient-centeredness of trials. We aim to use the context of the REAL-V study to identify possible factors that are associated with the experiences of patients having participated to this covid-19 related vaccination trial.
The expected outcome is to identify possible items for a Patient Reported Experience (PREM) measuring patient experience in a trial that could in a second phase be validated. To determine these items focus groups with patients participating to the last wave of REAL-V will be hold. During these group interviews the participants will be presented with the aspects identified in the literature associated with positive and negative trial participation experiences.